Quick Answer
AbCellera Biologics Inc. reported Net Income Loss of -$146.41 million for the year ending 2025.
- AbCellera Biologics Inc. showed an increase of +10.1% in Net Income Loss from 2024 to 2025.
- This data is from AbCellera Biologics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$2.09 million | Q2 2020: $6.70 million | Q3 2020: -$2.69 million | Q1 2021: $117.22 million | Q2 2021: -$2.32 million | Q3 2021: -$21.38 million | Q1 2022: $168.57 million | Q2 2022: -$6.79 million | Q3 2022: $26.62 million | Q1 2023: -$40.11 million | Q2 2023: -$30.53 million | Q3 2023: -$28.61 million | Q1 2024: -$40.61 million | Q2 2024: -$36.93 million | Q3 2024: -$51.11 million | Q1 2025: -$45.62 million | Q2 2025: -$34.73 million | Q3 2025: -$57.12 million.
- Over the full 7 years of available data (2019 to 2025), AbCellera Biologics Inc.'s Net Income Loss has declined by 6,522.0%.
- Historical annual values: Fiscal year 2025: -$146.41 million | Fiscal year 2024: -$162.86 million | Fiscal year 2023: -$146.40 million | Fiscal year 2022: $158.52 million | Fiscal year 2021: $153.46 million | Fiscal year 2020: $118.92 million | Fiscal year 2019: -$2.21 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: